

Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in Patients with Active Relapsing MS: Final Results from the Phase II ONWARD Study (P3.029)

Xavier Montalban, Bruce Cohen, Thomas Leist, Harold Moses, Christine Hicking, Fernando Dangond

First published April 4, 2016,

Abstract

Objective: To assess the efficacy of cladribine tablets (3.5mg/kg) as an add-on to IFN- β in patients with active relapsing MS **Background:** Cladribine tablets given annually for 2 years in short-duration courses to RRMS patients significantly improved clinical and MRI outcomes (CLARITY). In CLARITY Extension, the clinical benefits of 2-years of cladribine treatment (3.5mg/kg bodyweight) were maintained in the study for 4 years or more without further active treatment. ONWARD evaluated the safety/tolerability of cladribine tablets (3.5mg/kg) as an add-on to IFN- β therapy. Efficacy is reported here. **Methods:** ONWARD was a 2-year, randomized, double-blind Phase IIb study in patients aged 18-65 years, with ≥ 1 relapse during the prior 48 weeks while on IFN- β therapy, with EDSS scores 1.0-5.5 and normal blood cell counts within 28 days of baseline. **Results:** 14.5[percent] of patients (N=172) had SPMS at baseline. The mean number of qualifying relapses on study was lower (0.23) in patients treated with cladribine 3.5mg/kg plus IFN- β (N=124) vs. patients who received placebo plus IFN- β (0.56; N=48). The respective ARR_s were 0.12 (95[percent] CI 0.08, 0.17) and 0.32 (95[percent] CI 0.20, 0.45). Cladribine-treated patients were 63[percent] less likely to have a qualifying relapse ($P<0.001$). The proportion of patients with confirmed EDSS progression over 2 years was not significantly different for cladribine 3.5mg/kg plus IFN- β vs. placebo plus IFN- β ; however, the study was not powered for this endpoint. The mean numbers of new T1-Gd⁺, active T2 and CUA lesions/patient/scan were reduced in the combined treatment arm vs. placebo plus IFN- β . **Conclusions:** In patients with active relapsing MS with breakthrough disease while on IFN- β therapy (including SPMS with ongoing relapses), treatment with cladribine tablets added on to IFN- β demonstrated significant efficacy benefits. These results support the demonstrated efficacy of cladribine tablets in RRMS shown in CLARITY. Study supported by: Merck KGaA Darmstadt, Germany.

Disclosure: Dr. Montalban has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, EMD Serono, Genentech, Genzyme, Novartis, Sanofi Aventis, Teva Pharmaceutical, and Almirall. Dr. Cohen has received personal compensation for activities with Accorda, Astellis, Biogen-Idec, EMD Serono, Inc., and Genzyme. Dr. Leist has received research support from EMD Serono, Teva Neuroscience, Bayer Healthcare, ONO Pharmaceutical, Novartis, Daiichi, and Acorda Pharmaceuticals. Dr. Moses has received personal compensation for activities with EMD Serono, Teva Neuroscience, Biogen Idec, Bayer Pharmaceuticals, Novartis, Questcor, Actelion, Genzyme, and Acorda Therapeutics. Dr. Hicking has received personal compensation for

activities with Merck KGaA, Darmstadt, Germany as an employee. Dr. Dangond has received personal compensation for activities with EMD Serono, Inc. as an employee.

Monday, April 18 2016, 8:30 am-7:00 pm

- Copyright © 2016 by AAN Enterprises, Inc.

[Letters: Rapid online correspondence](#)

No comments have been published for this article.